TD Asset Management »

Summit Therapeutics shares owned by TD Asset Management

Quarter-by-quarter ownership of Summit Therapeutics (SMMT) shares owned by TD Asset Management from 13F filings

Historical chart of TD Asset Management investment in Summit Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Summit Therapeutics held by TD Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Summit Therapeutics by TD Asset Management

Quarter filed Position value Share count Share price at filing
2024-09-30 $15M 695k 20.89
2024-06-30 $2.1M 267k 7.80

More positions owned by TD Asset Management

Microsoft Corporation (MSFT)
Apple (AAPL)
Rbc Cad (RY)
Spdr S&p 500 Etf Tr Tr Unit (SPY)
NVIDIA Corporation (NVDA)
Toronto Dominion Bk Ont Com New (TD)
Meta Platforms Cl A (META)
Canadian Pacific Kansas City (CP)
Amazon (AMZN)
Bank Of Montreal Cadcom (BMO)
Enbridge (ENB)
Broadcom (AVGO)
Canadian Natural Resources (CNQ)
Cibc Cad (CM)
UnitedHealth (UNH)

View all positions for TD Asset Management

Top funds holding Summit Therapeutics

Baker Bros. Advisors
Vanguard Group
BlackRock
State Street Corporation
Geode Capital Management
T. Rowe Price Associates
Millennium Management
Caption Management
Standard Life Aberdeen
Balyasny Asset Management
Frigate Ventures
Charles Schwab Investment Management
Susquehanna International
TD Asset Management
QVT Financial

View all funds holding Summit Therapeutics